The worlds #1 website for end of day & historical stock data
wide range of exchanges, data formats, tools and services
API
NEW
HISTORICAL DATA
SYMBOL LISTS
MEMBERSHIP
REGISTER
LOG IN
Toggle navigation
HOME
Home Page
Download
Symbol Lists
Quote & Chart
Symbol Changes
Splits
Dividends
PRODUCTS & SERVICES
Membership Levels
Conversion Utility
API Service
Data Client
Historical Data
Fundamental Data
Commercial Feeds
Web Service
HOW TO
Advanced Get
AIQ
AMIBroker
EzyChart
MetaStock
OmniTrader
SuperCharts
TradeStation
SUPPORT
FAQ
Data Formats
Data Quality
Forgotten Password
Submit a Support Request
ABOUT
About Us
Contact Us
Terms & Conditions
Privacy Policy
Useful Links
MY ACCOUNT
Downloads
Account Details
API
Buy Historical Data
Billing History
Data Format
Daily Emails
Watchlists
MSE, PHM: Pharma Mar S.A.
05 Sep 2025
LAST:
88.40
CHANGE:
2.80
OPEN:
91.10
HIGH:
91.80
ASK:
0.00
VOLUME:
68.1K
CHG(%):
3.07
PREV:
91.20
LOW:
87.20
BID:
0.00
CHART
Period:
End of Day
Weekly
Monthly
Yearly
RECENT END OF DAY PRICES
Date
Open
High
Low
Close
Volume
05 Sep 25
91.10
91.80
87.20
88.40
68.1K
04 Sep 25
89.00
91.70
88.15
91.20
84.2K
03 Sep 25
85.25
88.60
85.25
88.60
85.5K
02 Sep 25
84.70
85.80
83.05
85.00
40.8K
01 Sep 25
81.15
86.80
81.15
84.00
104.1K
29 Aug 25
82.75
83.70
80.75
81.30
23.6K
28 Aug 25
80.10
83.65
79.70
82.85
61.4K
27 Aug 25
81.40
81.80
79.80
79.85
40.8K
25 Aug 25
81.65
81.90
81.25
81.55
16.4K
22 Aug 25
80.90
82.90
80.85
82.45
36.6K
COMPANY PROFILE
Name:
Pharma Mar S.A.
About:
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca is a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company develops Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating choroidal neovascularization, such as macular degeneration and diabetic retinopathy; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Sector:
Healthcare
Industry:
Biotechnology
Address:
Avenida de los Reyes, 1, Madrid, Spain, 28770
Website:
https://www.pharmamar.com
ISIN:
ES0169501022
LEI:
959800QWKZ45ZQC2AV58
SYMBOL HISTORY
Purchase End of Day History
for this symbol from Jan 01, 0001
Add to Watchlist
ADD TO WATCHLIST
Please select which Watchlist you would like to add this symbol to:
Watchlist:
DOWNLOAD DATA
Download stock quote history quickly and easily in a variety of formats to suit your needs.
Exchange:
American Stock Exchange
Australian Securities Exchange
Chicago Futures Exchange
Cryptocurrencies
EUREX Futures Exchange
Euronext - Amsterdam
Euronext - Brussels
Euronext - Lisbon
Euronext - Oslo
Euronext - Paris
Foreign Exchange
Frankfurt Exchange
Global Indices
LIFFE Futures and Options
London Stock Exchange
Madrid Stock Exchange
Minneapolis Grain Exchange
Mutual Funds
NASDAQ Stock Exchange
National Stock Exchange of India
New York Board of Trade
New York Stock Exchange
OTC Bulletin Board
Shanghai Stock Exchange
Shenzhen Stock Exchange
Singapore Stock Exchange
Toronto Stock Exchange
Toronto Venture Exchange
Winnipeg Commodity Exchange
Format:
3F VIP Trading
Advanced Get ASCII
AGet ASCII
AIQ Trading Expert Pro
Ami Broker
Ami Broker with Names
Andromeda
ASCII (Intraday)
EzyCharts
FCharts
FCharts (Intraday)
MetaStock ASCII (7 column)
MetaStock ASCII (8 column)
Metastock ASCII (Intraday)
MetaStock ASCII with Names
Personal Stock Streamer
Quicken
SpiffyCharts
Spreadsheet (eg: Excel)
Standard CSV
Stock Screener Pro
SuperCharts ASCII
Wal Data Platinum
Windows on Wallstreet
Period:
End of Day
1 Minute Bars
5 Minute Bars
10 Minute Bars
15 Minute Bars
30 Minute Bars
60 Minute Bars
Zip file
Symbol:
Start Date:
End Date:
Download
FUNDAMENTALS
P/E Ratio:
34.52
EPS Ratio:
2.40
DivYield:
0.01
Div/Share:
0.80
Price to Book:
7.17
Price to Sales:
7.63
EBITDA:
35.93M
Shares:
17.43M
Market Cap:
1.541B
TECHNICAL INDICATORS
MA5:
87.44
MA10:
84.52
MA20:
82.76
MA50:
81.48
MA100:
81.19
MA200:
82.73
STO9:
71.55
STO14:
71.55
RSI14:
59.90
WPR14:
-24.67
MTM14:
3.80
ROC14:
0.04
ATR:
3.03
Week High:
91.80
Week Low:
80.75
Month High:
91.80
Month Low:
77.30
Year High:
105.80
Year Low:
40.58
Volatility:
10.12